This company listing is no longer active
PCI Biotech Holding (PCIB) Stock Overview
A biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PCIB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
PCI Biotech Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.07 |
| 52 Week High | NOK 2.22 |
| 52 Week Low | NOK 0.055 |
| Beta | 0.79 |
| 1 Month Change | -63.45% |
| 3 Month Change | -73.98% |
| 1 Year Change | -95.33% |
| 3 Year Change | -96.50% |
| 5 Year Change | -99.71% |
| Change since IPO | -99.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| PCIB | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -54.8% | -1.3% | 2.2% |
| 1Y | -95.3% | 34.3% | 10.8% |
Return vs Industry: PCIB underperformed the Norwegian Biotechs industry which returned 44.5% over the past year.
Return vs Market: PCIB underperformed the Norwegian Market which returned 28.5% over the past year.
Price Volatility
| PCIB volatility | |
|---|---|
| PCIB Average Weekly Movement | 39.6% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in NO Market | 11.3% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: PCIB's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: PCIB's weekly volatility has increased from 26% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 5 | Ronny Skuggedal | www.pcibiotech.com |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases.
PCI Biotech Holding ASA Fundamentals Summary
| PCIB fundamental statistics | |
|---|---|
| Market cap | NOK 2.61m |
| Earnings (TTM) | -NOK 20.54m |
| Revenue (TTM) | NOK 4.69m |
Is PCIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCIB income statement (TTM) | |
|---|---|
| Revenue | NOK 4.69m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 4.69m |
| Other Expenses | NOK 25.23m |
| Earnings | -NOK 20.54m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.55 |
| Gross Margin | 100.00% |
| Net Profit Margin | -438.10% |
| Debt/Equity Ratio | 0% |
How did PCIB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/24 05:32 |
| End of Day Share Price | 2026/04/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PCI Biotech Holding ASA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.